Agios Pharmaceuticals executive sells shares worth $90,232

CAMBRIDGE, MA—Milanova Tsveta, Chief Commercial Officer at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold a portion of her company shares. According to a recent SEC filing, Tsveta sold 2,804 shares on January 6 at a price of $32.18 each, totaling $90,232. The stock has since risen to $35.12, with analysts setting price targets ranging from $46 to $75. InvestingPro analysis indicates the stock is currently undervalued, with 8 additional key insights available to subscribers. Following this transaction, she now holds 18,906 shares directly.

Earlier, on January 3, Tsveta acquired 8,476 shares of common stock through a stock option exercise, though this transaction did not involve any cash exchange as the stock price was set at $0. These shares were acquired as part of a restricted stock unit grant, with the transaction executed under a pre-established 10b5-1 plan to cover tax obligations related to vesting. According to InvestingPro data, Agios maintains a strong financial position with more cash than debt and a current ratio of 8.99x, though the company is currently burning through cash. Access the comprehensive Pro Research Report for detailed analysis of AGIO's financial health and growth prospects.

In other recent news, Agios Pharmaceuticals has made significant strides with its drug, PYRUKYND. The U.S. Food and Drug Administration (FDA) approved an update to the prescribing information for this drug, which now includes warnings and precautions about liver injury risks observed in patients treated for a condition different from its initially approved use.

Meanwhile, Agios also received EU orphan drug status for its sickle cell treatment, mitapivat. This designation emphasizes the potential of mitapivat to provide significant benefits. The results of the Phase 3 RISE UP study, which has completed enrollment, are eagerly awaited in late 2025.

In financial updates, Agios reported a significant increase in revenue for the third quarter of 2024, driven by milestone payments totaling $1.1 billion from the FDA approval of vorasidenib. The company plans to launch mitapivat for thalassemia in 2025 and sickle cell disease in 2026.

In the realm of stock analysis, RBC Capital raised the price target for Agios Pharma (NASDAQ:AGIO) from $55 to $57, maintaining an Outperform rating. This adjustment follows Agios Pharma's recent presentations, which highlighted promising clinical data. The firm's increased confidence in Agios Pharma is also bolstered by the positive reception of the ENERGIZE-T data and the strong case for regulatory approval consideration of mitapivat in thalassemia across four global regions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.